Karyopharm Therapeutics Clinical Trials

Company details

Status: Public
HQ: 85 Wells Avenue, Newton, MA 02459, US
Employees: 313
Programs: 82
Drugs: 53
Patents: 38

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026 Jun 2, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for Karyopharm Therapeutics.

Trial registry

99 studies

2023-506139-13-00
XPORT-MF-034

Phase 3 active small_molecule

Treatment naïve patients with MF

CTIS ↗
2024-511309-47-00
XPORT-MF-044

Phase 2 active small_molecule

moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

CTIS ↗
2024-511608-18-00
XPORT-MM-028

Phase 2 active small_molecule

Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

CTIS ↗
2024-512115-50-00
KCP-330-009

Phase 2 active other

Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

CTIS ↗
2024-513167-68-00
SELINEXOR for endometrial cancer

Phase 3 active small_molecule

endometrial cancer

CTIS ↗
2024-513605-31-00
SELINEXOR

Phase 2 active small_molecule

Myelofibrosis

CTIS ↗
2024-513616-95-00
XPORT-DLBCL-30

Phase 3 active small_molecule

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

CTIS ↗
NCT01607892
KPT-330

Phase 1 completed small_molecule

Hematological Malignancies

CT.gov ↗
NCT01607905
Selinexor

Phase 1 completed small_molecule

Solid Tumor

CT.gov ↗
NCT01896505
KCP-330

Phase 1 completed small_molecule

Sarcoma

CT.gov ↗
NCT01986348
Selinexor

Phase 2 terminated small_molecule

Glioblastoma

CT.gov ↗
NCT02025985
Selinexor

Phase 2 completed small_molecule

Ovarian Carcinoma

CT.gov ↗
NCT02078349
KPT-330

Phase 1 completed small_molecule

Solid Tumors

CT.gov ↗
NCT02088541
Selinexor

Phase 2 completed small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT02091245
KPT-330

Phase 1 active small_molecule

Relapsed Acute Lymphoblastic Leukemia (ALL)

CT.gov ↗
NCT02093403
decitabine

Phase 1 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT02120222
selinexor

Phase 1 completed small_molecule

Recurrent Melanoma

CT.gov ↗
NCT02137356
standard dose capecitabine

Phase 1 active small_molecule

Rectal Neoplasms

CT.gov ↗
NCT02138786
selinexor

Phase 2 terminated small_molecule

Richter's Transformation

CT.gov ↗
NCT02146833
Selinexor

Phase 2 terminated small_molecule

Prostate Cancer

CT.gov ↗
NCT02186834
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02212561
Selinexor

Phase 2 completed small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT02213133
Selinexor (KPT-330)

Phase 2 terminated small_molecule

Squamous Cell Carcinoma

CT.gov ↗
NCT02227251
Selinexor

Phase 2 active small_molecule

Diffuse Large B-cell Lymphoma

CT.gov ↗
NCT02228525
selinexor (KPT-330)

Phase 2 completed small_molecule

Myelodysplastic Syndromes

CT.gov ↗
NCT02249091
Selinexor

Phase 2 completed small_molecule

Acute Myeloid Leukemia (Relapsed/Refractory)

CT.gov ↗
NCT02250885
Selinexor

Phase 2 completed small_molecule

Carcinoma, Neuroendocrine

CT.gov ↗
NCT02299518
mitoxantrone hydrochloride

Phase 1 completed small_molecule

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

CT.gov ↗
NCT02303392
Selinexor

Phase 1 completed small_molecule

Prolymphocytic Leukemia

CT.gov ↗
NCT02314247
Selinexor

Phase 2 terminated small_molecule

Peripheral T-cell Lymphoma (PTCL)

CT.gov ↗
NCT02336815
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02343042
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02351505
Selinexor

Phase 2 terminated small_molecule

Recurrent Small Cell Lung Carcinoma

CT.gov ↗
NCT02367690
Selinexor

Phase 2 terminated small_molecule

Diabetic Foot Ulcers

CT.gov ↗
NCT02384850
Selinexor

Phase 1 terminated small_molecule

Colorectal Neoplasm

CT.gov ↗
NCT02389543
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02402764
Selinexor

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT02403310
Selinexor

Phase 2 completed small_molecule

Leukemia

CT.gov ↗
NCT02416908
Selinexor

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT02431351
Selinexor

Phase 2 terminated small_molecule

Myelodysplastic Syndrome

CT.gov ↗
NCT02431364
Verdinexor

Phase 1 terminated small_molecule

Healthy

CT.gov ↗
NCT02436707
Ibrutinib

Phase 2 active small_molecule

Lymphoma

CT.gov ↗
NCT02471911
KPT-330

Phase 1 completed small_molecule

Diffuse Large B-Cell Lymphoma

CT.gov ↗
NCT02530476
Selinexor

Phase 2 completed small_molecule

Leukemia

CT.gov ↗
NCT02536495
Docetaxel

Phase 2 terminated small_molecule

Recurrent Squamous Cell Lung Carcinoma

CT.gov ↗
NCT02606461
Selinexor

Phase 3 completed small_molecule

Dedifferentiated Liposarcoma

CT.gov ↗
NCT02628704
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02649790
KPT-8602

Phase 2 completed small_molecule

Relapsed/Refractory Multiple Myeloma (RRMM)

CT.gov ↗
NCT02702492
KPT-9274

Phase 1 terminated small_molecule

Solid Tumors

CT.gov ↗
NCT02741388
selinexor

Phase 1 completed small_molecule

B-cell Lymphoma

CT.gov ↗
NCT02780609
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT02831686
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT03042819
Selinexor

Phase 1 completed small_molecule

Soft Tissue Sarcoma

CT.gov ↗
NCT03071276
Selinexor

Phase 2 completed small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT03095612
Selinexor

Phase 2 terminated small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT03110562
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT03191981
Cyclophosphamide

Phase 2 terminated small_molecule

Myeloma Multiple

CT.gov ↗
NCT03193437
Open Label Selinexor

Phase 2 terminated small_molecule

Thymoma

CT.gov ↗
NCT03466827
Selinexor

Phase 2 active small_molecule

Thymoma

CT.gov ↗
NCT03555422
Selinexor

Phase 3 active small_molecule

Endometrial Cancer

CT.gov ↗
NCT03627403
Selinexor

Phase 2 terminated small_molecule

Primary Myelofibrosis

CT.gov ↗
NCT03732703
MyDRUG (MMRC-085)

Phase 2 completed small_molecule

Relapsed Refractory Multiple Myeloma

CT.gov ↗
NCT03880123
Selinexor

Phase 1 terminated small_molecule

Liposarcoma

CT.gov ↗
NCT03955783
Venetoclax

Phase 1 completed small_molecule

Diffuse Large B-cell Lymphoma

CT.gov ↗
NCT04256707
Selinexor 100 mg

Phase 2 completed small_molecule

Non-Small Cell Lung Carcinoma (NSCLC)

CT.gov ↗
NCT04349098
Selinexor

Phase 2 completed small_molecule

Coronavirus Infection

CT.gov ↗
NCT04355676
Selinexor

Phase 2 completed small_molecule

Coronavirus Infection

CT.gov ↗
NCT04414475
Selinexor

Phase 2 active small_molecule

Multiple Myeloma, Refractory

CT.gov ↗
NCT04421378
Selinexor

Phase 2 terminated small_molecule

Glioblastoma Multiforme

CT.gov ↗
NCT04442022
Selinexor (combination therapy)

Phase 3 active small_molecule

Relapsed/Refractory Diffuse Large B-cell Lymphoma

CT.gov ↗
NCT04519476
Selinexor

Phase 1 active small_molecule

Refractory Multiple Myeloma

CT.gov ↗
NCT04562389
Selinexor

Phase 2 active small_molecule

Myelofibrosis

CT.gov ↗
NCT04562870
Selinexor

Phase 2 active small_molecule

Myelofibrosis

CT.gov ↗
NCT04607772
Selinexor

Phase 2 terminated small_molecule

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CT.gov ↗
NCT04661137
Selinexor 60 MG

Phase 2 on hold small_molecule

Multiple Myeloma

CT.gov ↗
NCT04717700
Selinexor 20 MG Oral Tablet

Phase 2 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT04768881
Selinexor

Phase 2 terminated small_molecule

Locally Advanced Unresectable or Metastatic Melanoma

CT.gov ↗
NCT04782687
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT04843579
Selinexor

Phase 2 terminated small_molecule

Myeloma Multiple

CT.gov ↗
NCT04854434
Selinexor

Phase 2 terminated small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT04856189
Pembrolizumab

Phase 2 terminated mab

Advanced Urothelial Carcinoma

CT.gov ↗
NCT04898894
Venetoclax

Phase 1 active small_molecule

Acute Leukemia of Ambiguous Lineage in Relapse

CT.gov ↗
NCT04914845
KPT-9274

Phase 1 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04925193
Selinexor

Phase 2 active small_molecule

Multiple Myeloma in Relapse

CT.gov ↗
NCT04984330
Selinexor

Phase 1 terminated small_molecule

Amyloid

CT.gov ↗
NCT05028348
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT05093608
Selinexor Pill

Phase 1 terminated small_molecule

Hepatocellular Carcinoma

CT.gov ↗
NCT05170789
IST-342

Phase 2 terminated small_molecule

Relapsed Multiple Myeloma

CT.gov ↗
NCT05177276
Selinexor

Phase 2 terminated small_molecule

Solid Tumor Malignancy

CT.gov ↗
NCT05530421
Selinexor

Phase 2 active small_molecule

Relapsed and Refractory Multiple Myeloma

CT.gov ↗
NCT05597345
Selinexor

Phase 2 active small_molecule

Smoldering Multiple Myeloma

CT.gov ↗
NCT05611931
Selinexor

Phase 3 active small_molecule

Endometrial Cancer

CT.gov ↗
NCT05820763
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT05980806
Selinexor 60 mg

Phase 2 active small_molecule

Myelofibrosis

CT.gov ↗
NCT05983276
Decitabine

Phase 2 active small_molecule

Ovarian Cancer

CT.gov ↗
NCT06399640
Eltanexor

Phase 1 active small_molecule

Relapsed Myelodysplastic Syndrome

CT.gov ↗
NCT07200102
Selinexor

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT07447817
Pacritinib

Phase 2 active small_molecule

Myelofibrosis

CT.gov ↗
NCT07479979
Selinexor

Phase 2 active small_molecule

Relapse Multiple Myeloma

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma